Mesothelioma Empowerment Update - February 25, 2009
| Click here for Empowerment Archives! |
February 25, 2009
 |
Research grant announcement: Haining Yang, MD, PhD, a young scientist in the Cancer Research Center of Hawaii's Thoracic Oncology Program, was one of five recipients of a two-year $100,000 grant from Mesothelioma Applied Research Foundation (MARF). Her work has focused on the cellular interactions between asbestos fibers and human mesothelial cells. In addition she has been studying biomarkers that may lead to earlier detection of the disease and novel preventative therapies. More... |
Research grant announcement:
Haining Yang, MD, PhD, a young scientist in the Cancer Research Center of Hawaii's Thoracic Oncology Program, was one of five recipients of a two-year $100,000 grant from Mesothelioma Applied Research Foundation (MARF). Her work has focused on the cellular interactions between asbestos fibers and human mesothelial cells. In addition she has been studying biomarkers that may lead to earlier detection of the disease and novel preventative therapies. More...
Public Health:
Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Countries adopting asbestos bans reduced use rates about twice as fast as those not adopting bans.More...
Diagnosis / staging:
Malignant pleural diseases: diagnosis and treatment. Researchers evaluate efficacy of diagnostic procedures, results of surgery, and complications in malignant pleural diseases. More...
Chemotherapy:
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. Pemetrexed-pretreated patients with progressive malignant pleural mesothelioma may benefit from a consecutive chemotherapy with oxaliplatin and gemcitabine without significant toxicity. More...
In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma may possibly be applied to selecting the chemotherapy regimen for mesothelioma. More...
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. More...
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. More...
Surgery:
A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Aprotinin has been used to decrease blood loss with complicated cardiac surgery but has not been investigated in extrapleural pneumonectomy. More...
Treatment staging:
Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma During Treatment. More...
Immunotherapy:
Targeted Immune Cells Shrink Tumors in Mice. Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. More...
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. More...
Asbestos Law You Can Use
The following is a review of recent court decisions in various jurisdictions interpreting the responsibility of asbestos product manufacturers to persons harmed by their products. If you have questions or concerns about how any of these decisions may affect any asbestos injury claims which you may have, contact attorney John Caron at 1-800-831-9399 or jcaron@rgwpc.com.
- Machinery Manufacturers' Duty to Warn Severely Limited in Washington
- Pennsylvania "By-Stander's" Exposure Found Sufficient to Compel Auto Parts Manufacturers to Trial
- California Widow Held to Unfair Standard in Case Against Machinery Manufacturers
- More...
5th Annual Asbestos Awareness Day Conference: March 27-29 2009, Manhattan Beach, California A Reminder...
the Asbestos Disease Awareness Organization (ADAO) will be holding its 5th Annual Asbestos Awareness Day Conference on March 27-29, 2009 at the Manhattan Beach Marriott in Manhattan Beach, California.
This year's conference will feature expert speakers from around the globe addressing matters including identification and prevention of exposure, public health and environmental aspects of exposure and early warning symptoms of disease. Speaking on Saturday March 28 will be Dr. Robert Cameron, Director of the Mesothelioma Program at UCLA Medical Center in Los Angeles. In addition to being an innovator in the surgical management of mesothelioma, Dr. Cameron is a strong supporter of ADAO's focus on disease prevention. As the Scientific Director of the Pacific Heart, Lung & Blood Institute, Dr. Cameron is overseeing research into promising new strategies for preventing development of asbestos disease in exposed individuals.
The Law Office of Roger G. Worthington is proud to be an educational sponsor of this year's conference.
For further information or to register, go to www.AsbestosDiseaseAwareness.org
Worthington Supports Comeback of Floyd Landis, "The Bionic Man."
 |
The Law Office of Roger G. Worthington is pleased to announce its sponsorship of Floyd Landis and the OUCH pro cycling team.
"Floyd is not only one of the toughest athletes on the planet," said Roger Worthington. "He's also a warrior for justice with the battle scars to prove it."
Mr. Landis will make his return to professional cycling in the Amgen Tour of California, which he won in 2006. The race begins in Sacramento on February 15th and ends 7 days later in Escondido, California. The tour will feature the top cyclists in the world, including Lance Armstrong and Levi Leipheimer. More...